Milestone Pharmaceuticals -B (02181) has announced that one of its core products, CMAB009 Enlituximab (Xituximab beta injection), has received approval for its market registration application from the China National Medical Products Administration. It is used in combination with the FOLFIRI regimen as a first-line treatment for metastatic colorectal cancer with wild-type RAS/BRAF genes.
迈博药业-B(02181)：国家药监局批准核心产品CMAB009恩立妥(西妥昔单抗β注射液)的上市注册申请(NDA)
Mycophyto Pharmaceutical -B(02181): The State Drug Administration has approved the application for registration of the core product CMAB009 Enlituximab (Cetuximab beta injection).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.